Parakkal Deepak

Parakkal Deepak

Auto-generated profile, based on publicly available information

Parakkal Deepak

Washington University School of Medicine

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRita E. Chen
Rita E. Chen
XZXianwen Zhang
Xianwen Zhang
JCJames Brett Case
James Brett Case
EWEmma S. Winkler
Emma S. Winkler
YLYang Liu
Yang Liu
MDMichael Diamond
Michael Diamond

1 November 2021 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDParakkal Deepak
Parakkal Deepak
WKWooseob Kim
Wooseob Kim
MPMichael A. Paley
Michael A. Paley
MYMonica Yang
Monica Yang
ACAlexander B. Carvidi
Alexander B. Carvidi
AKAlfred Kim
Alfred Kim
Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients may be reduced. This study assessed the response to 2 doses of mRNA-based SARS-CoV-2 vaccine ... Visual Effect of Immunosuppression on Immunogenicity of mRNA SARS-CoV-2 Vaccines. Evidence suggests that immunogenicity to mRNA-based SARS-CoV-2 vaccination in immunosuppressed patients ma... Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive medications have increased risk for severe COVID-19. Although mRNA-based SARS-CoV-2 vaccination provides ...

12 March 2021 in Science
Verified
Journal Article
Closed access
PDF file
UJUmang Jain
Umang Jain
AHAaron M. Ver Heul
Aaron M. Ver Heul
SXShanshan Xiong
Shanshan Xiong
MGMartin H. Gregory
Martin H. Gregory
EDElora G. Demers
Elora G. Demers
TSThaddeus S. Stappenbeck
Thaddeus S. Stappenbeck
Fungal aggravation: The gut microbiota includes not only prokaryotes, viruses, protists, and occasionally helminths, but also fungi. The role that fungi play in this symbiosis has long been overlooked. While investigating alterations to the gut microbiota in mice with mucosal damage and human subjects with Crohn's disease, Jain et al. discovered the fungus Debaryomyces hansenii localized to wounds in inflamed mucosal tissue (see the Perspective by Chiaro and Round). Impaired healing was associated with antibiotic treatment, overgrowth of the fungus, and subsequent induction of a type I interferon–CCL5 axis by macrophages. The fungus was observed within macrophages. Such persistent injury stimulus is a hallmark of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. It is not known whether this salt-tolerant fungus is a natural symbiont, but it is used in the food industry for surface ripening of cheese and meat products. Science , this issue p. 1154 ; see also p. 1102

30 August 2021 in Autoimmunity Reviews
Verified
Journal Article
Closed access
AJAnuraag Jena
Anuraag Jena
SMShubhra Mishra
Shubhra Mishra
PDParakkal Deepak
Parakkal Deepak
PKPraveen Kumar-M
Praveen Kumar-M
ASAman Sharma
Aman Sharma
SSShaji Sebastian
Shaji Sebastian

3 July 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDParakkal Deepak
Parakkal Deepak
QAQuazim A. Alayo
Quazim A. Alayo
AKAava Khatiwada
Aava Khatiwada
BLBixuan Lin
Bixuan Lin
MFMarc Fenster
Marc Fenster
AYAndres Yarur
Andres Yarur

5 October 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
KWKimberly N Weaver
Kimberly N Weaver
MGMartin Gregory
Martin Gregory
GSGaurav Syal
Gaurav Syal
PHPatrick Hoversten
Patrick Hoversten
SHStephen Bradley Hicks
Stephen Bradley Hicks
EBEdward L Barnes
Edward L Barnes
Crohn’s disease (CD) of the pouch and chronic pouchitis occur in approximately 10% of patients after ileal pouch–anal anastomosis (IPAA) for refractory ulcerative colitis (UC) or UC-related dysplasia. The efficacy of anti–tumor necrosis factor (anti-TNF) agents and vedolizumab have been reported for the treatment of CD of the pouch and chronic pouchitis, but little is known regarding the use of ustekinumab in these settings. Our primary aim was to evaluate the efficacy of ustekinumab for these conditions. This is a retrospective, multicenter cohort study evaluating the efficacy of ustekinumab in patients with CD of the pouch and chronic pouchitis. Clinical response or remission was judged by the treating physician’s assessment at 6 months. Fifty-six patients (47 with CD of the pouch and 9 with chronic pouchitis) were included the study. Of these, 73% had previously been treated with either anti-TNF therapy, vedolizumab, or both after IPAA. Among patients with CD of the pouch and chronic pouchitis, 83% demonstrated clinical response 6 months after induction with ustekinumab. Responders demonstrated significantly less pouch inflammation on endoscopy when compared with nonresponders (29% vs 100%; P = 0.023). Higher mean body mass index at induction (26.3 vs 23.7; P = 0.033) and male sex (83% vs 30%; P = 0.014) were significant predictors of nonresponse to ustekinumab in those with CD of the pouch. In this refractory patient population, ustekinumab appears to be a safe and effective treatment for chronic pouchitis and CD of the pouch in biologic-naïve patients and those with prior anti-TNF or vedolizumab therapy failure.